We assayed the percentages of tumor T-cell infiltration of CD3+ , CD45+ , CD25+ , CD103+ , and CD39+ (Figs. 3A–E), to evaluate the systemic immune response after the primary tumors were subjected to PDT. This evidence concerns the gene ENTPD1 and neoplasm.